FDA moves to fast-track biosimilars, potentially lowering drug costs — but at what cost?

Estimated read time 1 min read

(NaturalNews) FDA proposes easing clinical trial requirements for biosimilars, allowing manufacturers to rely more on lab testing rather than costly human studi…

You May Also Like

More From Author